Beeline Medicines
Beeline Medicines is a clinical-stage biotechnology company developing afimetoran, an investigational oral, once-daily, equipotent small-molecule inhibitor of Toll-like receptors 7 and 8 (TLR7/8) for the treatment of lupus. The company's lead program met its primary endpoint in a global Phase 2 study in systemic lupus erythematosus, demonstrating higher SRI-4 response rates versus placebo at Week 48, and is now advancing into pivotal development for both systemic and cutaneous lupus.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Millions of people suffer from chronic immune-mediated conditions such as lupus that constrain daily life, drain energy, and put long-term health at risk. Progress in autoimmune and inflammatory disease has been too slow, leaving patients cycling through therapies that inadequately control disease and expose them to debilitating complications and organ damage.
Solution
Beeline Medicines is a clinical-stage biotechnology company developing precision therapies that target the underlying drivers of immune dysfunction. Its lead program, afimetoran, is a selective, oral, once-daily, equipotent small-molecule inhibitor of Toll-like receptors 7 and 8 (TLR7 and TLR8), targets that play critical and complementary roles in lupus pathogenesis. In a global Phase 2 trial, afimetoran met its primary endpoint, demonstrating significantly higher SRI-4 response rates versus placebo at Week 48 across all dose groups, along with consistent improvements across secondary endpoints. The therapy rapidly suppresses type I interferon signaling, dampens inflammatory cytokine networks, and modulates immune cell activation, including B cells. This direct engagement with a genetically validated pathway of lupus pathology potentially enables broad attenuation of underlying disease biology and holds promise to reduce steroid usage and the widespread organ damage associated with it.
Target Audience
Primary patients are people living with systemic lupus erythematosus and cutaneous lupus erythematosus, as well as the rheumatologists and dermatologists who treat them. The company also engages with clinical research sites and healthcare providers involved in lupus care.
Features
- Selective, equipotent small-molecule inhibitor of TLR7 and TLR8 with oral, once-daily administration
- Directly blocks genetically validated drivers of lupus pathology, reducing type I interferon production and pro-inflammatory cytokine release
- Phase 2 data showed higher SRI-4 response rates versus placebo at Week 48 (p<0.001 across all dose groups) with improvements across secondary endpoints
- Demonstrated exploratory efficacy in a Phase 1b study in cutaneous lupus erythematosus
- FDA Fast Track designation for systemic lupus erythematosus granted in May 2025
- Mechanism supports potential reduction in steroid usage and associated organ damage